Dr. Lockwood joined the staff of Baselodge Group in 2007 to guide and develop the company’s biotechnology and pharmaceutical outsourcing business.  He is available through Baselodge Group for consulting on any aspect of the nutraceutical and pharmaceutical development process.

Dr. Lockwood is a world-recognized expert in reactive oxygen species (ROS)-mediated disease and was most recently Chief Scientific Officer (CSO) and Co-Founder of Cardax Pharmaceuticals, Inc., a Hawaii-based drug discovery and development company. Cardax Pharmaceuticals, Inc., in a reverse merger, became Cardax, Inc. in February, 2014, thus becoming only the 16th public company in Hawaii (OTC:BB, symbol CDXI). Dr. Lockwood has twenty years of industry and clinical experience. Before co-founding Cardax Pharmaceuticals, Dr. Lockwood served as Medical Director for the private company Hawaii Biotech, Inc. (2002-2006), and the public biotech company Aquasearch, Inc. (2000-2002; now Mera Pharmaceuticals, Inc.).

Dr. Lockwood received Bachelor of Science degrees in Biology and Psychology from the University of Dayton, Dayton, Ohio; Master of Science degree in Evolutionary Genetics from Texas A&M University, College Station, Texas; and an M.D. from UTMB-Galveston, Texas with subsequent training in Emergency Medicine and Radiology.

Dr. Lockwood is primary inventor (see issued U.S. patents and global patents pending) on Cardax Pharmaceutical’s anti-inflammatory technology, and has co-authored more than 60 peer-reviewed articles, including multiple review articles and book chapters.

An extensive list of Dr. Lockwood’s publications, patents, and patent applications can be found on the . For reprints of scientific articles, please contact Dr. Lockwood at sflockwood [at] baselodge.com.